Study S002807

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered for 48 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

ClinicalTrials.gov record

Registration

Registration: NCT06525935
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 469
Start: 2024-08-16
Primary completion: 2025-12-08
Lead sponsor: Carmot Therapeutics, Inc.
Conditions: Obesity; Overweight
Interventions: DRUG:Placebo; DRUG:Enicepatide
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:XC45526

Registered primary outcomes

Percent Change in Body Weight from Baseline to Week 48 [Baseline to Week 48]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0039612	2813-LB: CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 Study Ildiko Lingvay, Diabetes	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06525935